Adaptive Biotechnologies Corporation

ADPT · NASDAQ

Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.

Follow Add to Watchlist Ask Question

NASDAQ ADPT Coverage Bootstrap Biotechnology Diagnostics Precision Medicine

Latest ReportMay 14, 2026Adaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?View report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.